ARS Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ARS Pharmaceuticals, Inc. (SPRY) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $12.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $12.80M, a 126.53% increase year-over-year.
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $7.83M, a 41.31% increase year-over-year.
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.97M, a 61.23% increase year-over-year.
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.65M, a 67.93% increase year-over-year.
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $23.17M, a 56.01% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $14.85M, a 58.91% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $9.35M, a 59.97% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.84M, a 106.54% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12.80M 10-Q · filed 2026-08-13 | $20.63M derived: sum of 2 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $7.83M 10-Q · filed 2026-08-13 | |||||
| 2025-12-31 | $23.17M 10-K · filed 2026-03-09 | |||||
| 2025-09-30 | $5.97M 10-Q · filed 2025-11-10 | $11.62M derived: sum of 2 quarters · filed 2026-08-13 | $17.16M derived: sum of 3 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $5.65M 10-Q · filed 2026-08-13 | $11.19M derived: sum of 2 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $5.54M 10-Q · filed 2026-08-13 | |||||
| 2024-12-31 | $14.85M 10-K · filed 2026-03-09 | |||||
| 2024-09-30 | $3.70M 10-Q · filed 2025-11-10 | $7.07M derived: sum of 2 quarters · filed 2025-11-10 | $10.38M derived: sum of 3 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $3.37M 10-Q · filed 2025-11-10 | $6.68M derived: sum of 2 quarters · filed 2025-11-10 | ||||
| 2024-03-31 | $3.31M 10-Q · filed 2025-11-10 | |||||
| 2023-12-31 | $9.35M 10-K · filed 2025-03-20 | |||||
| 2023-09-30 | $2.66M 10-Q · filed 2024-11-13 | $4.82M derived: sum of 2 quarters · filed 2024-11-13 | $7.07M derived: sum of 3 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $2.16M 10-Q · filed 2024-11-13 | $4.41M derived: sum of 2 quarters · filed 2024-11-13 | ||||
| 2023-03-31 | $2.25M 10-Q · filed 2024-11-13 | |||||
| 2022-12-31 | $5.84M 10-K · filed 2024-03-21 | |||||
| 2022-09-30 | $460.00K 10-Q · filed 2023-11-09 | $5.04M 10-Q · filed 2022-11-02 | $816.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.08M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $356.00K 10-Q · filed 2023-11-09 | $5.14M 10-Q · filed 2022-08-11 | $620.00K derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $264.00K 10-Q · filed 2023-11-09 | $4.95M 10-Q · filed 2022-05-12 | ||||
| 2021-12-31 | $2.83M 10-K · filed 2023-03-23 | $19.19M 10-K · filed 2022-03-31 | ||||
| 2021-09-30 | $5.02M 10-Q · filed 2022-11-02 | $9.75M derived: sum of 2 quarters · filed 2022-11-02 | $14.03M derived: sum of 3 quarters · filed 2022-11-02 | |||
| 2021-06-30 | $4.73M 10-Q · filed 2022-11-02 | $9.02M derived: sum of 2 quarters · filed 2022-11-02 | ||||
| 2021-03-31 | $4.29M 10-Q · filed 2022-11-02 | |||||
| 2020-12-31 | $2.64M 10-K · filed 2022-03-31 | |||||
| 2020-09-30 | $191.00K 10-Q · filed 2021-11-10 | $319.00K derived: sum of 2 quarters · filed 2021-11-10 | $366.00K derived: sum of 3 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $128.00K 10-Q · filed 2021-11-10 | $175.00K derived: sum of 2 quarters · filed 2021-11-10 | ||||
| 2020-03-31 | $47.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |